HIT Consultant – Read More
What You Should Know
- Value-based oncology leader Thyme Care has announced a comprehensive executive succession matrix: co-founder Robin Shah will transition to executive chairman, while current president and COO Brad Diephuis, M.D., will step into the CEO role, effective September 1, 2026.
- Dr. Diephuis, a primary care physician and cancer survivor, brings deep value-based policy expertise to the chief executive seat, having previously served as a senior advisor at the Center for Medicare and Medicaid Innovation (CMMI) where he helped design total cost of care frameworks like ACO REACH.
- To fill the operational vacancy, the company has recruited Marcia Macphearson as Chief Operating Officer, bringing 25 years of healthcare expertise from her previous roles as Chief Commercial Officer at Imagine Pediatrics and senior partner at Oliver Wyman.
Engineering Downstream Inpatient Diversion
The underlying architecture driving Thyme Care’s market expansion moves completely away from generic care navigation apps to enforce a rigid, clinically embedded model of whole-patient oversight. Founded in 2020 by Shah and prominent medical oncologist Bobby Green, M.D. (who continues as president and chief medical officer), the company operates by establishing full financial accountability across all 50 states.
Rather than functioning as an external, distracting vendor layer that causes provider friction, Thyme Care integrates its dedicated clinical teams and purpose-built software platform straight into existing practice workflows.
This complete integration allows Thyme Care to intercept acute complications in the critical moments between standard office appointments. The operational validation of this model is supported by strict, real-world data released in the company’s annual Impact Report today:
- Inpatient Reduction Moat: The platform achieves a verified 16% reduction in all-cause inpatient utilization for one national Medicare Advantage client’s eligible member cohort.
- Avoidable Readmission Prevention: For members completing Thyme Care’s specialized readmission prevention program, the technology drives a 30% drop in avoidable readmissions.
- Total Cost of Care Compression: By aligning treatment choice with clinical necessity, the infrastructure captures an immediate 10% decrease in total cost of care for partnering health plans.
“For too long, the responsibility for what happens in cancer care has been spread across so many parties that no one is connecting the dots for the person living through it,” stated Dr. Brad Diephuis, incoming CEO. “As CEO, I am committed to making sure that every patient, clinician, and health plan we work with experiences a system that finally moves together.”
CMMI Heritage: Weaponizing Policy for Commercial Scalability
The primary commercial advantage driving Thyme Care’s next phase of enterprise scaling sits within the unique policy background of its incoming chief executive. Dr. Diephuis is a primary care physician who previously served as a senior advisor at the Center for Medicare and Medicaid Innovation (CMMI), where he was central to shaping the nation’s total cost of care models, including the design of ACO REACH. This deep structural understanding of public sector risk management equips Thyme Care with an exceptional asset at a time when CMS is aggressively moving the entire market toward technology-enabled, outcomes-based chronic disease networks.
By pairing this CMMI policy design expertise with the operational execution of Marcia Macphearson—who spent a decade directing enterprise health plan strategy at consulting giant Oliver Wyman—Thyme Care is uniquely positioned to handle intense operational complexity.
As Robin Shah assumes the executive chairman seat to launch targeted solutions addressing drug price volatility and clinical trial access deficits, the platform leverages its massive 10.5 million covered life footprint to eliminate traditional administrative blind spots, providing employers and plan sponsors with complete real-time visibility into their actual longitudinal healthcare spend.
